Brief: vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights To Intellectual Property From Georgetown University
16/06/2023 13:07
June 16 (Reuters) - vTv Therapeutics Inc VTVT.O :
* VTV THERAPEUTICS PARTNER CANTEX PHARMACEUTICALS LICENSES
EXCLUSIVE RIGHTS TO INTELLECTUAL PROPERTY FROM GEORGETOWN
UNIVERSITY FOR AZELIRAGON AS A POTENTIAL TREATMENT FOR
CANCER-RELATED COGNITIVE DECLINE
Source text for Eikon: ID:nGNX7kdT50
Further company coverage: VTVT.O
(reuters.briefs@thomsonreuters.com)
Recent news on vTv Therapeutics
See all newsBrief: Vtv Therapeutics Announces FDA Orphan Drug Designation For Hppd In Sickle Cell Disease
vTv Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
vTv Therapeutics Inc expected to post a loss of $1.04 a share - Earnings Preview
vTv Therapeutics Q2 net loss widens on higher trial costs
Brief: VTv Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)